ITH is a biotech company located at the Karolinska Institutet and Karolinska University Hospital, dedicated to innovating the next generation of personalized therapeutics and diagnostics for patients with immune related diseases.
The company's research & development is focused on its award-winning Tailored Leukapheresis (TLA) immunotherapy for Immune Mediated Inflammatory Diseases - which has been developed with the support of the European Union, Swedish Research Council, and Swedish Governmental Agency for Innovation Systems.